Takeda throws DART back to MacroGenics

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated its option agreement and returned rights to bispecific antibody MGD010 to MacroGenics Inc. (NASDAQ:MGNX). The companies said the decision was not related to an ongoing Phase I study of the candidate to treat autoimmune disorders, and was part of a broader strategic shift for Takeda.

In July, Takeda said it will "reduce and concentrate" its R&D in Japan and the U.S. In recent years, the pharma has winnowed down its disease focus to CNS, cancer and gastrointestinal disease, plus vaccines (see BioCentury Extra, July 29). ...